Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Projected health and economic impacts of sugar-sweetened beverage taxation in Germany: A cross-validation modelling study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science, [2004]-
    • الموضوع:
    • نبذة مختصرة :
      Background: Taxes on sugar-sweetened beverages (SSBs) have been implemented globally to reduce the burden of cardiometabolic diseases by disincentivizing consumption through increased prices (e.g., 1 peso/litre tax in Mexico) or incentivizing industry reformulation to reduce SSB sugar content (e.g., tiered structure of the United Kingdom [UK] Soft Drinks Industry Levy [SDIL]). In Germany, where no tax on SSBs is enacted, the health and economic impact of SSB taxation using the experience from internationally implemented tax designs has not been evaluated. The objective of this study was to estimate the health and economic impact of national SSBs taxation scenarios in Germany.
      Methods and Findings: In this modelling study, we evaluated a 20% ad valorem SSB tax with/without taxation of fruit juice (based on implemented SSB taxes and recommendations) and a tiered tax (based on the UK SDIL) in the German adult population aged 30 to 90 years from 2023 to 2043. We developed a microsimulation model (IMPACTNCD Germany) that captures the demographics, risk factor profile and epidemiology of type 2 diabetes, coronary heart disease (CHD) and stroke in the German population using the best available evidence and national data. For each scenario, we estimated changes in sugar consumption and associated weight change. Resulting cases of cardiometabolic disease prevented/postponed and related quality-adjusted life years (QALYs) and economic impacts from healthcare (medical costs) and societal (medical, patient time, and productivity costs) perspectives were estimated using national cost and health utility data. Additionally, we assessed structural uncertainty regarding direct, body mass index (BMI)-independent cardiometabolic effects of SSBs and cross-validated results with an independently developed cohort model (PRIMEtime). We found that SSB taxation could reduce sugar intake in the German adult population by 1 g/day (95%-uncertainty interval [0.05, 1.65]) for a 20% ad valorem tax on SSBs leading to reduced consumption through increased prices (pass-through of 82%) and 2.34 g/day (95%-UI [2.32, 2.36]) for a tiered tax on SSBs leading to 30% reduction in SSB sugar content via reformulation. Through reductions in obesity, type 2 diabetes, and cardiovascular disease (CVD), 106,000 (95%-UI [57,200, 153,200]) QALYs could be gained with a 20% ad valorem tax and 192,300 (95%-UI [130,100, 254,200]) QALYs with a tiered tax. Respectively, €9.6 billion (95%-UI [4.7, 15.3]) and €16.0 billion (95%-UI [8.1, 25.5]) costs could be saved from a societal perspective over 20 years. Impacts of the 20% ad valorem tax were larger when additionally taxing fruit juice (252,400 QALYs gained, 95%-UI [176,700, 325,800]; €11.8 billion costs saved, 95%-UI [€6.7, €17.9]), but impacts of all scenarios were reduced when excluding direct health effects of SSBs. Cross-validation with PRIMEtime showed similar results. Limitations include remaining uncertainties in the economic and epidemiological evidence and a lack of product-level data.
      Conclusions: In this study, we found that SSB taxation in Germany could help to reduce the national burden of noncommunicable diseases and save a substantial amount of societal costs. A tiered tax designed to incentivize reformulation of SSBs towards less sugar might have a larger population-level health and economic impact than an ad valorem tax that incentivizes consumer behaviour change only through increased prices.
      Competing Interests: KMFEF, BAC, NW, JL, MS, AP, LJC, MOF, CK, and ML report no support from any organisation for the submitted work. PS reports funding support from the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre (BRC); BAC reports funding support from the NIHR, Medical Research Council (MRC), National Health Service (NHS) and Wellcome Trust; BAC reports consulting fees from NESTA and UNICEF; BAC reports internal committee positions in the Nuffield Department of Population Health, University of Oxford and membership in the Doctoral Training Partnerships Representatives of the MRC; KMFEF, NW, MS, AP, LJC, MOF, PS, CK and ML report no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; JL reports membership in the scientific board and lead of working groups of the German Nutrition Society (DGE) and membership in the Scientific Advisory Board of the Federal Ministry of Food and Agriculture (BMEL); all authors report no other relationships or activities that could appear to have influenced the submitted work.
      (Copyright: © 2023 Emmert-Fees et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Lancet. 2019 May 11;393(10184):1958-1972. (PMID: 30954305)
      Lancet. 2011 Aug 27;378(9793):826-37. (PMID: 21872751)
      PLoS One. 2013 Jul 30;8(7):e65174. (PMID: 23935815)
      BMC Health Serv Res. 2019 Jul 16;19(1):485. (PMID: 31307442)
      Am J Clin Nutr. 1997 Apr;65(4 Suppl):1220S-1228S; discussion 1229S-1231S. (PMID: 9094926)
      Med Decis Making. 2012 Sep-Oct;32(5):733-43. (PMID: 22990088)
      PLoS Med. 2020 Feb 11;17(2):e1003025. (PMID: 32045418)
      BMJ. 2023 Apr 19;381:e073406. (PMID: 37076174)
      Diabet Med. 2020 Oct;37(10):1752-1758. (PMID: 31834643)
      BMJ. 2015 Jul 21;351:h3576. (PMID: 26199070)
      Health Aff (Millwood). 2019 Nov;38(11):1824-1831. (PMID: 31682510)
      Gesundheitswesen. 2005 Aug;67 Suppl 1:S19-25. (PMID: 16032513)
      BMC Public Health. 2017 Jan 17;17(1):88. (PMID: 28095809)
      Pharmacoeconomics. 2019 Nov;37(11):1305-1312. (PMID: 31347104)
      Ann Nutr Metab. 2023;79(3):282-290. (PMID: 36809753)
      JAMA. 2017 Mar 7;317(9):912-924. (PMID: 28267855)
      PLoS Med. 2016 Apr 05;13(4):e1001990. (PMID: 27046234)
      Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Jan;63(1):93-102. (PMID: 31792553)
      Circulation. 2020 Aug 11;142(6):523-534. (PMID: 32564614)
      Circulation. 2019 Jun 4;139(23):2613-2624. (PMID: 30982338)
      Eur Heart J. 2021 Jul 1;42(25):2439-2454. (PMID: 34120177)
      N Engl J Med. 2012 Oct 11;367(15):1397-406. (PMID: 22998340)
      Health Econ. 2020 Oct;29(10):1289-1306. (PMID: 33463850)
      BMJ Open Diabetes Res Care. 2021 Jan;9(1):. (PMID: 33455907)
      Br J Nutr. 2015 May 28;113(10):1603-14. (PMID: 25866161)
      BMJ. 2018 Jun 13;361:k2426. (PMID: 29898890)
      Diabetes Care. 2018 May;41(5):971-978. (PMID: 29348194)
      JAMA Netw Open. 2021 Nov 1;4(11):e2132271. (PMID: 34739061)
      PLoS One. 2017 Mar 1;12(3):e0172277. (PMID: 28249003)
      Eur Heart J. 2021 Jul 1;42(25):2455-2467. (PMID: 34120185)
      Br J Nutr. 2015 Mar 14;113(5):709-17. (PMID: 25735740)
      Lancet. 2011 Aug 6;378(9790):515-25. (PMID: 21481448)
      Eur J Clin Nutr. 2019 Dec;73(12):1556-1560. (PMID: 31636410)
      Lancet Public Health. 2016 Dec 16;2(1):e15-e22. (PMID: 28804786)
      BMJ Open. 2016 Nov 21;6(11):e012527. (PMID: 27872118)
      PLoS Med. 2023 Apr 18;20(4):e1004212. (PMID: 37071600)
      Diabet Med. 2020 May;37(5):895-897. (PMID: 31829456)
      Ann Intern Med. 2019 Dec 3;171(11):796-804. (PMID: 31683314)
      Am J Public Health. 2019 Feb;109(2):276-284. (PMID: 30571305)
      JAMA. 2016 Sep 13;316(10):1093-103. (PMID: 27623463)
      PLoS Med. 2023 Jan 26;20(1):e1004160. (PMID: 36701272)
      Tob Control. 2023 Sep;32(5):589-598. (PMID: 35017262)
      Milbank Q. 2009 Mar;87(1):229-57. (PMID: 19298422)
      Ann Nutr Metab. 2017;71(3-4):164-174. (PMID: 28930718)
      PLoS Med. 2017 Feb 14;14(2):e1002232. (PMID: 28196089)
      JAMA Netw Open. 2022 Jun 1;5(6):e2215276. (PMID: 35648398)
      Am J Public Health. 2013 Nov;103(11):1954-61. (PMID: 24028228)
      Lancet. 2017 Mar 25;389(10075):1229-1237. (PMID: 28159391)
      Front Nutr. 2019 Sep 06;6:145. (PMID: 31552261)
      PLoS One. 2017 Apr 27;12(4):e0175149. (PMID: 28448503)
      BMJ. 2018 May 29;361:k934. (PMID: 29844013)
      Econ Hum Biol. 2020 May;37:100856. (PMID: 32070906)
      BMJ. 2021 Mar 10;372:n254. (PMID: 33692200)
      Hepatology. 2021 Jun;73(6):2180-2195. (PMID: 30959577)
      Adv Nutr. 2021 Oct 1;12(5):1957-1995. (PMID: 33873201)
      PLoS One. 2021 Aug 19;16(8):e0253748. (PMID: 34411108)
      Med Decis Making. 2012 Sep-Oct;32(5):722-32. (PMID: 22990087)
      J Dent Res. 2016 Nov;95(12):1327-1332. (PMID: 27671690)
      Annu Rev Nutr. 2019 Aug 21;39:317-338. (PMID: 31116649)
      Value Health. 2021 Feb;24(2):274-280. (PMID: 33518034)
      Popul Health Metr. 2003 Apr 14;1(1):4. (PMID: 12773212)
      J Health Monit. 2021 Sep 15;6(3):26-44. (PMID: 35146315)
      Curr Opin Clin Nutr Metab Care. 2011 Jul;14(4):385-90. (PMID: 21519237)
      Obes Rev. 2013 Nov;14 Suppl 2:159-68. (PMID: 24103073)
      Nat Rev Endocrinol. 2022 Apr;18(4):205-218. (PMID: 35064240)
      PLoS Med. 2018 May 29;15(5):e1002573. (PMID: 29813056)
      J Am Coll Cardiol. 2015 Oct 6;66(14):1615-1624. (PMID: 26429086)
      Eur J Public Health. 2022 Nov 28;32(Suppl 4):iv84-iv91. (PMID: 36444112)
      J Nutr Educ Behav. 2019 Nov - Dec;51(10):1177-1187. (PMID: 31402290)
      Diabet Med. 2013 Oct;30(10):1245-9. (PMID: 23796224)
      J Epidemiol Community Health. 2019 Sep;73(9):881-887. (PMID: 31320459)
      Lancet. 2014 Mar 15;383(9921):970-83. (PMID: 24269108)
      Nervenarzt. 2008 Aug;79(8):918-20, 922-4, 926. (PMID: 18528673)
      Am J Clin Nutr. 2013 Oct;98(4):1084-102. (PMID: 23966427)
      BMJ Open. 2017 Jan 24;7(1):e013791. (PMID: 28119387)
      Value Health. 2022 Jan;25(1):3-9. (PMID: 35031096)
      Public Health Nutr. 2022 Jun;25(6):1691-1700. (PMID: 34881689)
    • الرقم المعرف:
      0 (Sugars)
    • الموضوع:
      Date Created: 20231121 Date Completed: 20231127 Latest Revision: 20231127
    • الموضوع:
      20231215
    • الرقم المعرف:
      PMC10662751
    • الرقم المعرف:
      10.1371/journal.pmed.1004311
    • الرقم المعرف:
      37988392